Insider buying last 90 days
No open-market insider purchases were filed for IMVT in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Immunovant reported fiscal second-quarter results on 9 November, topping estimates with an EPS of ($0.47) against a projected ($0.74) loss. The quarter's focus was IMVT-1402, which met its primary endpoint in a trial for difficult-to-treat rheumatoid arthritis, with FDA discussions planned later this year for its registrational program. Roivant's call also disclosed $31 million in net revenue from the initial launch of LISRAYA, alongside a Form 8K filing tied to the announcement and coverage noting a prior setback in the cutaneous lupus erythematosus program ahead of this report.
Shares closed at $35.15, up 15.1% on the day, trading above both the 50-day average of $32.98 and the 200-day average of $32.17, with the 50-day above the 200-day. The GekkoIndex reading sits at 48.3, placing it in the Neutral zone, and the stock trades essentially in line with Gekko Fair Value of $35.19, a gap of -0.1%.
No confirmed earnings date is on the calendar for the next 20 trading days, and no insider, Congress, or unusual options activity appears in the current window. Seasonality over the past 5 years shows an average 20-day return of 1.3% from this point, rising in 2 of those years. Analyst coverage currently shows 6 buy and 3 hold ratings among 9 firms, with a consensus target of $48.88.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Immunovant scores 3 supportive, 2 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive2 mixed0 headwinds
Above 50 and 200-day
Close $34.18 is above the 50-day ($32.64) and 200-day ($32.35) averages, and the 50-day is above the 200-day.
See the chart51.9, Neutral
Reading 51.9 is in the Neutral zone.
See the GekkoIndex3.1% below
Price is within 5% of Gekko Fair Value (3.1% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 82 days
Next report Feb 5, 2027, 82 days away — outside a typical 20-trading-day hold.
See earnings+7.2% on average
From this point in the calendar, the next 20 trading days averaged +7.2% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Immunovant closed at $34.18 on Nov 13, 2026, +45.8% over the past year, inside a 52-week range of $21.86 to $45.42.
Use the left and right arrow keys to read daily values.
Put IMVT on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Immunovant develops monoclonal antibody treatments aimed at autoimmune diseases and remains in the clinical testing stage of drug development. Its lead candidate, batoclimab, is a fully human antibody designed to block the neonatal fragment crystallizable receptor, known as FcRn, which plays a role in a number of autoimmune conditions. The company is best recognized for this program, which spans several disease areas rather than a single condition.
Batoclimab is being studied in Phase IIa trials for myasthenia gravis and thyroid eye disease, and has entered Phase II testing for warm autoimmune hemolytic anemia. Immunovant operates as a subsidiary of Roivant Sciences Ltd, situating its research within that broader corporate structure rather than as a fully independent entity.
The company was founded in 2018 and is headquartered in New York, New York. Its shares are listed on the NASDAQ under the ticker IMVT.
Immunovant’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 51.9, in the Neutral zone, down 6.8 points over five sessions.
Down 6.8 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 76 | −1.0% | −4.3% | ||
| Accumulation | 247 | −0.8% | −2.9% | ||
| Neutral (current zone) | 350 | +1.0% | +3.2% | ||
| Distribution | 28 | −2.5% | −4.0% | ||
| Selling | 1 | Too few readings yet | |||
Average IMVT share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Immunovant trades 3.1% below Gekko Fair Value of $35.29, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Immunovant shares are worth, recalculated every trading day.
$35.29
Gekko Fair Value, Nov 14, 2026
3.1% below fair value · About fair value
At the end of Aug 2026 the price was 11.0% below the estimate.
No open-market insider purchases were filed for Immunovant, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for IMVT in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in IMVT were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
1of the funds Gekko tracks holds IMVT.
Immunovant reports on Feb 5, 2027, before the open (82 days away), and beat the EPS estimate in 3 of its last 8 reports.
Feb 5, 2027
Expected before the open, 82 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | −$0.75 est −$0.66 | $7.10M est $7.10M | +1.7% |
| May 20, 2026 | −$0.67 est −$0.63 | — | +29.8% |
| Feb 6, 2026 | −$0.54 est −$0.69 | — est $6.00M | +14.3% |
| Nov 10, 2025 | −$0.73 est −$0.72 | — | −2.0% |
| Aug 11, 2025 | −$0.60 est −$0.69 | — | −1.6% |
| May 29, 2025 | −$0.64 est −$0.71 | — | +5.3% |
| Feb 6, 2025 | −$0.76 est −$0.75 | — | −9.3% |
| Nov 7, 2024 | −$0.74 est −$0.61 | — | −2.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Immunovant is $48.50, +41.9% from the last close, from 9 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 9 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 12 | J.P. Morgan | $49 | +43.4% |
| Nov 10 | Truist Financial | $33 | −3.5% |
| Nov 10 | H.C. Wainwright | $41 | +20.0% |
| Nov 10 | Wells Fargo | $47 | +37.5% |
| Nov 9 | Bank of America Securities | $46 | +34.6% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Immunovant averaged +7.2% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −4.0% | 1 of 5 |
| Next 10 trading days | −0.1% | 2 of 5 |
| Next 15 trading days | +3.8% | 2 of 5 |
| Next 20 trading days | +7.2% | 3 of 5 |
| Next 30 trading days | +9.0% | 3 of 5 |
For scale, IMVT’s typical 20-trading-day move in either direction is about 10.1%.
Immunovant’s market cap is $7.07B and revenue of $0 over the last twelve months.
Coverage of Immunovant this week reads positive: 5 positive, 2 neutral and 2 negative headlines.
Immunovant’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 19.9% below |
| GILDGilead Sciences | Neutral | 11.7% above |
| MRNAModerna | Neutral | 21.1% above |
| NTRANatera | Accumulation | 18.6% below |
| IQVIQVIA | Accumulation | 5.0% above |
| UTHRUnited Therapeutics | Neutral | 11.2% below |
A peer links to its own page where one exists.
Immunovant’s market cap is $7.07B at the Nov 13, 2026 close of $34.18, with 206.9M shares outstanding.
The consensus analyst 12-month price target for Immunovant is $48.50, +41.9% from the last close. Of the 9 firms that rated the stock in the last 90 days, 6 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Immunovant is about fair value: the Nov 13, 2026 close of $34.18 is 3.1% below Gekko Fair Value of $35.29. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Immunovant is expected to report on Feb 5, 2027, before the market opens (82 days away). Analysts expect earnings of −$0.68 per share. Immunovant beat the earnings estimate in 3 of its last 8 reports, moving 8.3% on average across the report.
Immunovant’s 52-week high is $45.42 and its 52-week low is $21.86; it closed at $34.18 on Nov 13, 2026, +45.8% over the past year. Over the last five years the shares peaked at $45.58 on Jan 9, 2024.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, earnings risk and seasonality), 2 as mixed (gekkoindex and fair value). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.